We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+9.82%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.17B
AUM Growth
+$18.3M
Cap. Flow
-$273M
Cap. Flow %
-4.42%
Top 10 Hldgs %
39.22%
Holding
178
New
12
Increased
57
Reduced
71
Closed
15

Top Buys

Rank Stock Value
1
EVH icon
Evolent Health
EVH
+$25.8M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$23.3M
3
EXAS
Exact Sciences
EXAS
+$16.4M
4
ABT icon
Abbott
ABT
+$15.1M
5
TNDM icon
Tandem Diabetes Care
TNDM
+$13M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$36.6M
2
BIO icon
Bio-Rad Laboratories Class A
BIO
+$34.7M
3
CRL icon
Charles River Laboratories
CRL
+$33.2M
4
ARGX icon
argenx
ARGX
+$29.8M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$28.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.92%
2 Industrials 0.04%
3 Communication Services 0.02%
4 Technology 0.01%
5 Consumer Discretionary 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
1
argenx
ARGX
$53.8B
$343M 5.56%
632,829
-59,045
-9% -$29.8M
IONS icon
2
Ionis Pharmaceuticals
IONS
$8.99B
$315M 5.11%
7,874,400
-386,034
-5% -$18M
VRTX icon
3
Vertex Pharmaceuticals
VRTX
$123B
$266M 4.31%
571,406
-22,055
-4% -$10.6M
ISRG icon
4
Intuitive Surgical
ISRG
$122B
$244M 3.95%
496,775
-43,129
-8% -$20.1M
ALNY icon
5
Alnylam Pharmaceuticals
ALNY
$35.7B
$223M 3.61%
809,095
-110,739
-12% -$28.8M
RVMD icon
6
Revolution Medicines
RVMD
$39.6B
$221M 3.58%
4,871,360
-157,740
-3% -$6.87M
NBIX icon
7
Neurocrine Biosciences
NBIX
$17.2B
$215M 3.48%
1,863,800
-34,840
-2% -$4.78M
BSX icon
8
Boston Scientific
BSX
$65.4B
$206M 3.33%
2,452,797
-116,791
-5% -$9.21M
ABT icon
9
Abbott
ABT
$175B
$199M 3.22%
1,743,938
+137,785
+9% +$15.1M
SYK icon
10
Stryker
SYK
$123B
$190M 3.08%
526,607
-19,327
-4% -$6.67M
ITCI
11
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$182M 2.95%
2,485,627
+14,342
+0.6% +$1.08M
AGIO icon
12
Agios Pharmaceuticals
AGIO
$2.36B
$166M 2.69%
3,735,915
-143,633
-4% -$6.52M
INCY icon
13
Incyte
INCY
$23.4B
$142M 2.3%
2,150,551
-2,953
-0.1% -$188K
UNH icon
14
UnitedHealth
UNH
$387B
$132M 2.14%
225,550
+19,875
+10% +$11.2M
MRNA icon
15
Moderna
MRNA
$24.5B
$107M 1.73%
1,600,836
+37,101
+2% +$3.41M
CLDX icon
16
Celldex Therapeutics
CLDX
$2.77B
$104M 1.69%
3,071,615
+100,000
+3% +$3.81M
BHVN icon
17
Biohaven
BHVN
$2.32B
$102M 1.65%
2,040,853
– –
EXAS
18
DELISTED
Exact Sciences
EXAS
$98.7M 1.6%
1,449,465
+290,585
+25% +$16.4M
CDNA icon
19
CareDx
CDNA
$2.05B
$98.2M 1.59%
3,145,456
-767,119
-20% -$19.1M
PODD icon
20
Insulet
PODD
$11.4B
$98.1M 1.59%
421,479
-13,941
-3% -$2.86M
MDT icon
21
Medtronic
MDT
$106B
$90.8M 1.47%
1,008,633
+6,886
+0.7% +$579K
BDX icon
22
Becton Dickinson
BDX
$43.6B
$81.4M 1.32%
337,633
-9,700
-3% -$2.27M
TNDM icon
23
Tandem Diabetes Care
TNDM
$1.17B
$78.5M 1.27%
1,850,891
+307,624
+20% +$13M
EVH icon
24
Evolent Health
EVH
$654M
$75.5M 1.22%
2,670,050
+1,000,215
+60% +$25.8M
EW icon
25
Edwards Lifesciences
EW
$49.4B
$74.8M 1.21%
1,134,076
-126,385
-10% -$9.18M
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2024 Portfolio in Review

As of Q3 2024, Bellevue Group held 178 positions worth $6.17B, up 0.3% from $6.15B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Bellevue Group withdrew a net $273M in Q3 2024, closing 15 positions and reducing 71 holdings. Its most notable exit was Silk Road Medical, Inc. Common Stock, an estimated $23.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Industrials and Communication Services.

Against the trend, Bellevue Group opened a new position in Terns Pharmaceuticals worth $8.69M.

  • Bellevue Group's largest Q3 2024 buy was Terns Pharmaceuticals: 1,042,135 shares worth $8.69M.
  • Bellevue Group added most to Evolent Health in Q3 2024, an estimated $25.8M increase.
  • Bellevue Group's biggest Q3 2024 reduction was Insmed, cutting an estimated $36.6M.
  • Bellevue Group fully exited Silk Road Medical, Inc. Common Stock in Q3 2024, selling an estimated $23.1M.
  • Bellevue Group's ten largest holdings make up 39% of its $6.17B portfolio in Q3 2024.
  • Bellevue Group opened 12 new positions and closed 15 in Q3 2024.
  • Bellevue Group's portfolio value rose 0.3% quarter-over-quarter to $6.17B.

Based on Bellevue Group's 13F filing for Q3 2024, filed 14 Nov 2024.